The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study
Open accessAbstract
Background Neurofibrillary pathology has a stereotypical progression in Alzheimer's disease (AD) that is encapsulated in the Braak staging scheme; however, some AD cases are atypical and do not fit into this scheme. We aimed to compare clinical and neuropathological features between typical and atypical AD cases.Methods AD cases with a Braak neurofibrillary tangle stage of more than IV were identified from a brain bank database. By use of thioflavin-S fluorescence microscopy, we assessed the density and the distribution of neurofibrillary tangles in three cortical regions and two hippocampal sectors. These data were used to construct an algorithm to classify AD cases into typical, hippocampal sparing, or limbic predominant. Classified cases were then compared for clinical, demographic, pathological, and genetic characteristics. An independent cohort of AD cases was assessed to validate findings from the initial cohort.Findings 889 cases of AD, 398 men and 491 women with age at death of 37-103 years, were classified with the algorithm as hippocampal sparing (97 cases [11%]), typical (665 [75%]), or limbic predominant (127 [14%]). By comparison with typical AD, neurofibrillary tangle counts per 0.125 mm(2) in hippocampal sparing cases were higher in cortical areas (median 13, IQR 11-16) and lower in the hippocampus (7.5, 5.2-9.5), whereas counts in limbic-predominant cases were lower in cortical areas (4.3, 3.0-5.7) and higher in the hippocampus (27, 22-35). Hippocampal sparing cases had less hippocampal atrophy than did typical and limbic-predominant cases. Patients with hippocampal sparing AD were younger at death (mean 72 years [SD 10]) and a higher proportion of them were men (61 [63%]), whereas those with limbic-predominant AD were older (mean 86 years [SD 6]) and a higher proportion of them were women (87 [69%]). Microtubule-associated protein tau (MAPT) H1H1 genotype was more common in limbic-predominant AD (54 [70%]) than in hippocampal sparing AD (24 [46%]; p=0.011), but did not differ significantly between limbic-predominant and typical AD (204 [59%]; p=0.11). Apolipoprotein E (APOE) ɛ4 allele status differed between AD subtypes only when data were stratified by age at onset. Clinical presentation, age at onset, disease duration, and rate of cognitive decline differed between the AD subtypes. These findings were confirmed in a validation cohort of 113 patients with AD.Interpretation These data support the hypothesis that AD has distinct clinicopathological subtypes. Hippocampal sparing and limbic-predominant AD subtypes might account for about 25% of cases, and hence should be considered when designing clinical, genetic, biomarker, and treatment studies in patients with AD.Funding US National Institutes of Health via Mayo Alzheimer's Disease Research Center, Mayo Clinic Study on Aging, Florida Alzheimer's Disease Research Center, and Einstein Aging Study; and State of Florida Alzheimer's Disease Initiative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“clinical features lack specificity for a pathologic process, but rather indicate brain regions or systems affected by the disease process [3, 4].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three major subtypes of AD can be classified by the relative density of hippocampal neurofibrillary tangles with respect to neocortical tangles [3].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Genetic analyses of APOE suggest APOE4 is more closely linked to typical or limbic predominant than hippocampal sparing AD [3].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Nonamnestic clinical presentations, that is, language, visuospatial, and executive disorders, may also be due to AD [63–66].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [65]
In the citing paper
“Another challenge of CPC studies is that the molecular, anatomic, and clinical changes of AD may not progress in a uniform fashion (7, 12-15).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [12]
In the citing paper
“and that not all AD cases fall within the same spatial continuum with regard to brain NFT distributions (12, 15, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [12]
In the citing paper
“Nevertheless, Braak staging also masks the fact that marked variability in pathologic lesion density across cases exists within a given Braak stage (7, 12)”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916
Self-citationAssociation of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781
Self-citationBarker, W., Luis, C. A., Kashuba, A., Luis, M., Harwood, D. G., Loewenstein, D., Waters, C., Jimison, P., Shepherd, E., Sevush, S., et al. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200210000-00001 · Cited by 714
Self-citation
Cited by
Sorted by citations
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
“Genetic analyses of APOE suggest APOE4 is more closely linked to typical or limbic predominant than hippocampal sparing AD [3].”
BackgroundInfluentialSelf-citationAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
“It remains to be determined whether these individuals died early in the course of an idiosyncratic subtype of AD (12) or instead reflect a completely different pathogenesis.”
BackgroundPathology of Neurodegenerative Diseases
Dugger, B. N., & Dickson, D. W. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028035 · Cited by 1,665
Self-citationPrimary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467
Self-citationPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Clinical Neurology and Epidemiology of the Major Neurodegenerative DiseasesPreprint
Erkkinen, M. G., Kim, M., & Geschwind, M. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,231
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103
“This is a useful addition, although other clinically and neuropathologically defined AD subtypes have not been addressed (51).”
BackgroundTau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Alzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Ferriani, M. D. G. C. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 1,031
Brain atrophy in Alzheimer’s Disease and aging
Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., Galluzzi, S., Marizzoni, M., & Frisoni, G. B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.002 · Cited by 836
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
McKeith, I. G., Ferman, T. J., Thomas, A. J., Blanc, F., Boeve, B. F., Fujishiro, H., Kantarci, K., Muscio, C., O'Brien, J. T., Postuma, R. B., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009323 · Cited by 782
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
Bejanin, A., Schonhaut, D. R., La Joie, R., Kramer, J. H., Baker, S. L., Sosa, N., Ayakta, N., Cantwell, A., Janabi, M., Lauriola, M., et al. (2017) · Brain · doi:10.1093/brain/awx243 · Cited by 778
Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755
“Not all AD cases fall within the standard NFT distribution described by the Braak staging (Hof et al., 1997; Abner et al., 2011; Murray et al., 2011).”
BackgroundFour distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Self-citationArendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.057 · Cited by 622
La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612
Young, A. L., Marinescu, R. V., Oxtoby, N. P., Bocchetta, M., Yong, K., Firth, N. C., Cash, D. M., Thomas, D. L., Dick, K. M., Cardoso, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05892-0 · Cited by 596
Self-citationRaja, W. K., Mungenast, A. E., Lin, Y.-T., Ko, T., Abdurrob, F., Seo, J., & Tsai, L.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161969 · Cited by 569
Babulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
Self-citationSpread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
Vogel, J. W., Iturria‐Medina, Y., Strandberg, O. T., Smith, R. A., Levitis, E., Evans, A. C., Hansson, O., Initiative, A. D. N., Weiner, M. W., Aisen, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15701-2 · Cited by 537
Self-citationThe probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Invited review: Neuropathology of tauopathies: principles and practice
Kovacs, G. G. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12208 · Cited by 492
TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. F., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1269-z · Cited by 481
Self-citationAn autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Self-citationAhmed, Z., Cooper, J., Murray, T. K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M. A., Cavallini, A., Jackson, S., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1254-6 · Cited by 484
Whitwell, J. L., Dickson, D. W., Murray, M. E., Weigand, S. D., Tosakulwong, N., Senjem, M. L., Knopman, D. S., Boeve, B. F., Parisi, J. E., Petersen, R. C., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70200-4 · Cited by 419
Self-citationBiological subtypes of Alzheimer disease
Ferreira, D., Nordberg, A. K., & Westman, E. (2020) · Neurology · doi:10.1212/wnl.0000000000009058 · Cited by 427
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
Sadick, J. S., O’Dea, M. R., Hasel, P., Dykstra, T., Faustin, A., & Liddelow, S. A. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.008 · Cited by 415
Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS
Prudencio, M., Belzil, V., Batra, R., Ross, C. A., Gendron, T. F., Pregent, L., Murray, M. E., Overstreet, K., Johnston, A., Desaro, P., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4065 · Cited by 396
Self-citationPrimary progressive aphasia and the evolving neurology of the language network
Mesulam, M. M., Rogalski, E. J., Wieneke, C., Hurley, R. S. E., Geula, C., Bigio, E. H., Thompson, C. K., & Weıntraub, S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.159 · Cited by 406
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Lam, B., Masellis, M., Freedman, M., Stuss, D. T., & Black, S. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt155 · Cited by 386
Neuropathology of Alzheimer's Disease
Trejo‐Lopez, J. A., Yachnis, A. T., & Prokop, S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01146-y · Cited by 419
TDP-43 Pathology in Alzheimer’s Disease
Meneses, A. D., Koga, S., O’Leary, J., Dickson, D. W., Bu, G., & Zhao, N. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00503-x · Cited by 374
Self-citationMendez, M. F. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.005 · Cited by 389
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357
Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer’s disease
Chen, J.-F., Liu, K., Hu, B., Li, R.-R., Xin, W., Chen, H., Wang, F., Chen, L., Li, R.-X., Ren, S.-Y., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.012 · Cited by 346
Lehmann, M., Ghosh, P. M., Madison, C., Laforce, R., Corbetta-Rastelli, C., Weiner, M. W., Greicius, M. D., Seeley, W. W., Gorno-Tempini, M. L., Rosen, H. J., et al. (2013) · Brain · doi:10.1093/brain/aws327 · Cited by 325
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324
Self-citationOECD (2015) · OECD health policy studies · doi:10.1787/9789264231726-en · Cited by 343
Kovács, G. G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020189 · Cited by 346
The complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 343
PART is part of Alzheimer disease
Duyckaerts, C. J., Braak, H., Brion, J., Buée, L., Tredici, K. D., Goedert, M., Halliday, G. M., Neumann, M., Spillantini, M. G., Tolnay, M., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1390-7 · Cited by 329
Böhle, M., Eitel, F., Weygandt, M., & Ritter, K. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00194 · Cited by 291
Cook, C. N., Carlomagno, Y., Gendron, T. F., Dunmore, J. H., Scheffel, K., Stetler, C. T., Davis, M., Dickson, D. W., Jarpe, M. B., Deture, M. A., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt402 · Cited by 325
Self-citationLewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Early-onset Alzheimer Disease and Its Variants
Mendez, M. F. (2019) · Continuum · doi:10.1212/con.0000000000000687 · Cited by 307
Murray, M. E., DeJesus‐Hernandez, M., Rutherford, N. J., Baker, M. C., Duara, R., Graff‐Radford, N. R., Wszołek, Z. K., Ferman, T. J., Josephs, K. A., Boylan, K., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0907-y · Cited by 301
Self-citationComorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease
Spina, S., La Joie, R., Petersen, C., Nolan, A. L., Cuevas, D., Cosme, C., Hepker, M., Hwang, J.-H., Miller, Z. A., Huang, E. J., et al. (2021) · Brain · doi:10.1093/brain/awab099 · Cited by 278
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β
Therriault, J., Benedet, A. L., Pascoal, T. A., Mathotaarachchi, S., Chamoun, M., Savard, M., Thomas, E., Kang, M. S., Lussier, F., Tissot, C., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4421 · Cited by 256
18F-MK-6240 PET for early and late detection of neurofibrillary tangles
Pascoal, T. A., Therriault, J., Benedet, A. L., Savard, M., Lussier, F. Z., Chamoun, M., Tissot, C., Qureshi, M. N. I., Kang, M. S., Mathotaarachchi, S. S., et al. (2020) · Brain · doi:10.1093/brain/awaa180 · Cited by 263
Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 266
Molecular pathology of neurodegenerative diseases: principles and practice
Kovács, G. G. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205952 · Cited by 255
Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum
Jones, D. T., Graff‐Radford, J., Lowe, V. J., Wiste, H. J., Gunter, J. L., Senjem, M. L., Botha, H., Kantarci, K., Boeve, B. F., Knopman, D. S., et al. (2017) · Cortex · doi:10.1016/j.cortex.2017.09.018 · Cited by 239
Self-citationClinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Murray, M. E., Kouri, N., Lin, W.-L., Jack, C. R., Dickson, D. W., & Vemuri, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt231 · Cited by 249
Self-citationAlzheimer's Disease-Like Pathology Induced by Amyloid-β Oligomers in Nonhuman Primates
Forny‐Germano, L., Silva, N. M. L. E., Batista, A. F., Brito‐Moreira, J., Gralle, M., Boehnke, S. E., Coe, B. C., Lablans, A., Marques, S. A., Martinez, A. M. B., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1353-14.2014 · Cited by 245
Tang, Z., Chuang, K. V., DeCarli, C. S., Jin, L., Beckett, L. A., Keiser, M. J., & Dugger, B. N. (2019) · Nature Communications · doi:10.1038/s41467-019-10212-1 · Cited by 234
Ferreira, D., Verhagen, C., Hernandez-Cabrera, J. A., Cavallin, L., Guo, C., Ekman, U., Muehlboeck, J., Simmons, A., Barroso, J., Wahlund, L., et al. (2017) · Scientific Reports · doi:10.1038/srep46263 · Cited by 230
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802395-2.00025-0 · Cited by 225
Lewis, J. M., & Dickson, D. W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1507-z · Cited by 229
Self-citationHigher Rates of Decline for Women and Apolipoprotein E ε4 Carriers
Holland, D., Desikan, R. S., Dale, A. M., & McEvoy, L. K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3601 · Cited by 219
Predicting Alzheimer's disease progression using deep recurrent neural networks
Nguyen, M., He, T., An, L., Alexander, D. C., Feng, J., Yeo, B. T. T., & Initiative, F. T. A. D. N. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117203 · Cited by 231
Varol, E., Sotiras, A., & Davatzikos, C. A. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.02.041 · Cited by 217
Raj, A., LoCastro, E., Kuceyeski, A. F., Tosun, D., Relkin, N. R., & Weiner, M. W. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.034 · Cited by 210
The paradox of syndromic diversity in Alzheimer disease
Warren, J. D., Fletcher, P. D., & Golden, H. L. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.135 · Cited by 204
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Therriault, J., Schindler, S. E., Salvadó, G., Pascoal, T. A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Apostolova, L. G., Murray, M. E., Verberk, I. M. W., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00942-2 · Cited by 225
Self-citationEarly neurone loss in Alzheimer’s disease: cortical or subcortical?
Arendt, T., Brückner, M. K., Morawski, M., Jäger, C., & Gertz, H. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0187-1 · Cited by 209
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
Boeve, B. F. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70054-1 · Cited by 211
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease
Nelson, P. T., Smith, C. D., Abner, E. L., Wilfred, B. R., Wang, W., Neltner, J. H., Baker, M., Fardo, D. W., Kryscio, R. J., Scheff, S. W., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1154-1 · Cited by 201
Early-Onset Alzheimer’s Disease: What Is Missing in Research?
Ayodele, T., Rogaeva, E. A., Kurup, J. T., Beecham, G. W., & Reitz, C. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01090-y · Cited by 210
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer’s Disease
Edmonds, E. C., Initiative, A. D. N., Delano‐Wood, L., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150128 · Cited by 205
Emrani, S., Arain, H. A., DeMarshall, C. A., & Nuriel, T. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00712-4 · Cited by 207
Is Alzheimer disease a disease?
Korczyn, A. D., & Grinberg, L. T. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00940-4 · Cited by 198
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
Self-citationAnatomical heterogeneity of Alzheimer disease
Noh, Y., Jeon, S., Lee, J. M., Seo, S. W., Kim, G. H., Cho, H., Ye, B. S., Yoon, C. W., Kim, H. J., Chin, J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001003 · Cited by 183
Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease
Möller, C., Vrenken, H., Jiskoot, L. C., Versteeg, A., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.013 · Cited by 187
Early onset Alzheimer’s disease is associated with a distinct neuropsychological profile
Smits, L. L., Pijnenburg, Y. A. L., Koedam, E. L. G. E., van der Vlies, A. E., Reuling, I. E. W., Koene, T., Teunissen, C. E., Scheltens, P., & van der Flier, W. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111934 · Cited by 182
Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease
Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185
Zhang, X., Mormino, E. C., Sun, N., Sperling, R. A., Sabuncu, M. R., Yeo, B. T. T., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611073113 · Cited by 174
Self-citationDong, A., Toledo, J. B., Honnorat, N., Doshi, J. J., Varol, E., Sotiras, A., Wolk, D. A., Trojanowski, J. Q., Davatzikos, C. A., & Initiative, A. D. N. (2016) · Brain · doi:10.1093/brain/aww319 · Cited by 183
Nelson, P. T., Brayne, C., Flanagan, M. E., Abner, E. L., Agrawal, S., Attems, J., Castellani, R. J., Corrada, M. M., Cykowski, M. D., Di, J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02444-1 · Cited by 187
Self-citationFerrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.
Jellinger, K. A., Alafuzoff, I., Attems, J., Beach, T. G., Cairns, N. J., Crary, J. F., Dickson, D. W., Hof, P. R., Hyman, B. T., Jack, C. R., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1407-2 · Cited by 171
Self-citationPatient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease
Franzmeier, N., Dewenter, A., Frontzkowski, L. K., Dichgans, M., Rubinski, A., Neitzel, J., Smith, R. A., Strandberg, O. T., Ossenkoppele, R., Büerger, K., et al. (2020) · Science Advances · doi:10.1126/sciadv.abd1327 · Cited by 178
Heterogeneous patterns of brain atrophy in Alzheimer's disease
Poulakis, K., Pereira, J. B., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Soininen, H. S., Lovestone, S., Simmons, A., Wahlund, L., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.009 · Cited by 160
Josephs, K. A., Murray, M. E., Tosakulwong, N., Whitwell, J. L., Knopman, D. S., Machulda, M. M., Weigand, S. D., Boeve, B. F., Kantarci, K., Petrucelli, L., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1681-2 · Cited by 169
Self-citationDisentangling Heterogeneity in Alzheimer’s Disease and Related Dementias Using Data-Driven Methods
Habes, M., Grothe, M. J., Tunc, B., McMillan, C., Wolk, D. A., & Davatzikos, C. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.016 · Cited by 167
Early-onset Alzheimer's Disease: Nonamnestic Subtypes and Type 2 AD
Mendez, M. F. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.009 · Cited by 181
Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline
Risacher, S. L., Anderson, W. H., Charil, A., Castelluccio, P. F., Shcherbinin, S., Saykin, A. J., Schwarz, A. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M. W., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004670 · Cited by 163
Self-citation[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159
Self-citationBhagwat, N., Viviano, J. D., Voineskos, A. N., Chakravarty, M. M., & Initiative, A. D. N. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006376 · Cited by 157
The basis of cellular and regional vulnerability in Alzheimer’s disease
Mrdjen, D., Fox, E. J., Bukhari, S. A., Montine, K. S., Bendall, S. C., & Montine, T. J. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02054-4 · Cited by 162
Matěj, R., Tesař, A., & Rusina, R. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.005 · Cited by 164
Metadata
- Authors
- Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W.
- Affiliations
- Mayo Clinic (US)
- Mount Sinai Medical Center (US)
- Corresponding author
- Dickson, Dennis W
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 10
- Issue
- 9
- Pages
- 785-796
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC3175379
- OpenAlex
- W2075444764
- Cited by
- 972
- References
- 44
- Citations by year
- 2026: 60 · 2025: 80 · 2024: 78 · 2023: 96 · 2022: 80 · 2021: 104 · 2020: 70 · 2019: 73 · 2018: 56 · 2017: 50 · 2016: 55 · 2015: 37 · 2014: 36 · 2013: 54 · 2012: 35
- FWCI
- 29.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Mayo Clinic
- National Institutes of Health
- National Institute on Aging (P50‐AG16574, U01AG06786, P50 AG215711, P01AG03949, U01AG006786, P01AG003949, R21AG038736, P50AG025711, P01AG017216, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P50NS072187)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, Braak staging, hippocampal sparing, hippocampal atrophy, tau pathology, clinical features, atypical Alzheimer's disease, sex differences, age at death, genetic risk factors
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Hippocampus, Humans, Limbic System, Male, Middle Aged, Retrospective Studies, Cohort Studies, Neurofibrillary Tangles, tau Proteins, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
